Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Emergent Biosolutions
(NY:
EBS
)
10.74
+2.08 (+24.02%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Emergent Biosolutions
< Previous
1
2
3
4
Next >
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
August 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
August 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
July 31, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
July 24, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
July 23, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Watch These 4 Overbought Stocks As Market Rotation Continues
July 18, 2024
Recent market rotations and sector-specific outflows have created a ripe environment for potential pullbacks despite the market's 17% YTD gain.
Via
MarketBeat
Topics
ETFs
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
July 09, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
July 02, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
July 02, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
June 20, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
June 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
May 10, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports First Quarter 2024 Financial Results
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
May 01, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
April 30, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
April 22, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
March 28, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
March 25, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
March 06, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
February 29, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Inc. (NYSE: EBS) is One of Wednesday Morning’s Most Active Stocks
February 21, 2024
Via
Investor Brand Network
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
February 21, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
January 11, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
January 09, 2024
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
November 28, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
November 24, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
November 08, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
October 30, 2023
From
Emergent BioSolutions
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.